Clinical Trials

Melanoma, Skin Neoplasms

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

46 enrolled

CNSDermatologicHead & NeckThoracic

Solid Tumors

NCT05355701 2026-03-27

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

267 enrolled

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

98 enrolled 18 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

38 enrolled

921 enrolled 48 charts 2 FDA

Melanoma, Skin Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

DermatologicGastrointestinal

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

336 enrolled

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

34 enrolled 44 charts

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05195632 2026-01-07

OCEANII

63 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04913285 2025-12-24

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

400 enrolled

DermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Thyroid Diseases

NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

65 enrolled 52 charts

CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Other solid neoplasmThoracic

58 enrolled

Solid Tumor

NCT05340621 2025-03-07

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

36 enrolled

Melanoma

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

11 enrolled

Tumor-Agnostic

Neoplasms

NCT03374254 2024-11-21

KEYNOTE-651

116 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT04800822 2024-10-22

PF-07284892 in Participants With Advanced Solid Tumors

CNSGastrointestinalThoracic

53 enrolled

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT03864042 2024-09-27

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

56 enrolled 158 charts

Melanoma

NCT04965818 2024-09-19

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05810740 2024-09-19

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

37 enrolled 25 charts

Melanoma

NCT01543698 2024-03-13

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

189 enrolled 44 charts

Solid Tumors Harboring a BRAF V600 Mutation

NCT02159066 2024-03-05

LOGIC-2

158 enrolled 40 charts

Melanoma

NCT03693170 2024-02-02

ANCHOR-CRC

95 enrolled 30 charts

Colorectal Neoplasms

NCT01320085 2024-01-24

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

183 enrolled 35 charts

702 enrolled 82 charts 3 FDA

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT02928224 2023-12-21

BEACON CRC

Phase 3 Completed

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT05270044 2023-11-22

COLUMBUS-AD

815 enrolled

Melanoma

NCT01849874 2023-10-30

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 3 Terminated

341 enrolled 15 charts

Gynecologic

Low-grade Serous Ovarian Cancer

NCT03911869 2023-05-31

POLARIS

Phase 2 Terminated

13 enrolled 55 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03878719 2023-04-03

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

1 enrolled

Melanoma

NCT04759846 2023-02-21

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Phase 1 Withdrawn

Melanoma

NCT03637491 2022-01-26

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

36 enrolled 22 charts

Pancreatic Neoplasms

NCT05080621 2022-01-05

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Phase 1/2 Withdrawn

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03271047 2022-01-04

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

75 enrolled 17 charts

Tumor-Agnostic

Neoplasms

NCT05103891 2021-12-01

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Phase 1 Unknown

14 enrolled

Melanoma

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Phase 3 Completed

402 enrolled 21 charts

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

NCT01885195 2021-02-21

SIGNATURE

Other hematologic neoplasmThoracic

110 enrolled 18 charts

Noonan Syndrome 5, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01927341 2021-02-18

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

53 enrolled 17 charts

Colorectal Neoplasms

NCT02276027 2020-12-16

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

66 enrolled 18 charts

Adenocarcinoma of Lung

NCT01562899 2020-12-10

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

77 enrolled

Melanoma

NCT01337765 2020-10-09

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

29 enrolled

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

BreastGastrointestinalGynecologic

89 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01469130 2020-10-05

A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

21 enrolled

Advanced Solid Tumor

NCT01352273 2020-09-30

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

69 enrolled

Advanced Solid Tumors

NCT00959127 2020-09-16

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

93 enrolled

Biliary Tract Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01801358 2020-09-16

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

38 enrolled 31 charts

Uveal Melanoma, Melanoma

NCT01649336 2020-09-14

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

36 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01449058 2017-10-02

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

139 enrolled